Pneumonia vaccine study aims to sharpen lab tests
NCT ID NCT07205289
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study will give 12 healthy adults a killed whole-cell pneumococcal vaccine called Gamma-PN. The main goal is to collect blood samples to help develop and validate lab tests that measure immune responses. The study does not aim to prove the vaccine works in people, but rather to improve tools for future vaccine research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gamma-PN (killed whole-cell pneumococcal vaccine)
What this could lead to
If successful, this study will help create better lab tests to measure immune responses to pneumococcal vaccines, supporting future vaccine development.
What could go wrong
This is a very early Phase 1 study with only 12 participants, focused on lab test development rather than proving the vaccine works. Results may not translate to larger populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE, INVASIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Adelaide Clinical Research Facility
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact